Scientists used an AI program called Evo to design 16 novel viruses by analyzing trillions of DNA and RNA nucleotides. While the breakthrough could advance medical treatments for diseases and drug-resistant bacteria, researchers warn of biosecurity risks if the technology is misused to create bioweapons.
OpenAI's claim that GPT-6 Astra achieved 99.9% on the ARC Prize benchmark relied on a different software harness than the standard test environment, which produced a 62.7% score. The same model weights scored dramatically higher with OpenAI's custom harness due to superior context management and tool access, raising questions about fair comparison with prior models and prompting ARC Prize to reject AGI claims and commit to publishing both harness results.